Section Arrow
Quote
MNMD.NASDAQ
- Mind Medicine (MindMed)
Quotes are at least 15-min delayed:2025/07/22 03:05 EDT
Regular Hours
Last
 9.95
+1.07 (+12.05%)
Day High 
10.24 
Prev. Close
8.88 
1-M High
9.195 
Volume 
3.33M 
Bid
--
Ask
--
Day Low
8.96 
Open
8.98 
1-M Low
6.345 
Market Cap 
670.91M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 8.13 
20-SMA 7.48 
50-SMA 7.26 
52-W High 10.4362 
52-W Low 4.7 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.75/-2.24
Enterprise Value
692.77M
Balance Sheet
Book Value Per Share
2.95
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TNFATNF Pharmaceuticals Inc.0.1294+0.0419+47.89%-- 
NCNANuCana plc0.051+0.0033+6.92%-- 
PMNProMIS Neurosciences1.12+0.6799+154.49%5PE
SABSSAB Biotherapeutics2.7+0.13+5.06%-- 
RXRXRecursion Pharmaceuticals6.4+0.56+9.59%-- 
Quotes are at least 15-min delayed：2025/07/22 03:05 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.